Binaytara Foundation Announces 2022 Award Recipients For Excellence In Cancer Care

Binaytara Foundation Announces 2022 Award Recipients For Excellence In Cancer Care

For more information contact:
Tara Shah
(425) 557-5953
support@binayfoundation.org

Seattle, WA, March 24, 2022 – The Binaytara Foundation, a non-profit organization that works to improve equity in cancer care, has announced their 2022 award recipients for excellence in cancer care. Every year, the Binaytara Foundation awards outstanding individuals who have worked alongside the foundation to minimize cancer disparities. This year’s recipients have achieved success in several distinct areas:

Julie Gralow, MD, FACP, FASCO, the Chief Medical Officer of the American Society of Clinical Oncology, will receive the Binaytara Foundation Humanitarian Award for demonstrating the highest values of volunteerism, community engagement, and dedication to improving access to cancer care globally.

Both Bhawna Sirohi, MBBS, FRCP from Apollo Proton Cancer Center (India), and Shaji Kumar, MD, a Professor of Medicine from the Mayo Clinic, will receive the Distinguished Faculty award. Dr. Sirohi and Dr. Kumar have both demonstrated long-standing excellence in teaching and improving access to education for health care providers.

The foundation’s Rising Star in Health Equity awards will be given to Joseph Rosales, MD from Virginia Mason Cancer Institute, and Aparna Parikh, MD from Massachusetts General Hospital. Both Dr. Rosales and Dr. Parikh have demonstrated exceptional leadership in improving cancer care in underprivileged communities.

Finally, the Volunteer of the Year award will be given to Jody Stroh, MBA for her selfless and dedicated service to advancing the mission of the Binaytara Foundation to improve access to cancer care through exceptional leadership and volunteerism.

 

Binaytara Foundation president Dr. Binay Shah says, “The Binaytara Foundation exists to minimize cancer disparities, and we are blessed to have so many supporters who deeply care about improving access to cancer care. I am incredibly grateful to all our awardees for their support of our mission and dedication to improving access to cancer care, here in the United States, and globally. Congratulations to all of our recipients! Together, we will save thousands of lives.”

The recipients will receive their awards at the Binaytara Foundation’s annual gala dinner, which will be held on April 30th, 2022. The gala takes place during the foundation’s 2022 Summit on Cancer Health Disparities. More information about the gala dinner can be found here.

The 2022 Summit on Cancer Health Disparities will bring together oncology professionals, cancer disparity researchers, and other stakeholders to discuss the factors leading to cancer health disparities. Additionally, they will explore ways to overcome the impact of these factors to optimize outcomes of cancer patients. To register for the 2022 Summit on Cancer Health Disparities, please click here.

About Binaytara Foundation:

Binaytara Foundation is a global cancer non-profit dedicated to improving access to cancer care in the United States and abroad through education and innovative program models that break down barriers and advance best practices in hematology and oncology. Binaytara Foundation’s major projects include hematology and oncology conferences, and the establishment of a cancer hospital in Nepal.

Staff Writer - The Cancer News

Recent Posts

ADRIATIC: durvalumab (D) as consolidation treatment (tx) for patients (pts) with limited-stage small-cell lung cancer (LS-SCLC)

By: Tiantian Zhang1, Yiqun Han2, Lei Deng3 1. Department of Internal Medicine, University of Central…

7 months ago

ASCO24 LAURA Trial Summary

By: Zhiting Tang1, Lei Deng21. Unity Hospital, Rochester Regional Health, Rochester, NY2. University of Washington/Fred…

7 months ago

FDA Approves Tovorafenib for Pediatric Low-Grade Glioma With BRAF Mutation

By: Dr. Anish Shah Bronx-Lebanon Hospital; Bronx, NY On April 23, 2024, the U.S. Food and Drug…

7 months ago

FDA Approves Tisotumab Vedotin for Recurrent or Metastatic Cervical Cancer

By: Dr. Anish Shah Bronx-Lebanon Hospital; Bronx, NY On April 29, 2024, the U.S. Food and Drug…

7 months ago

FDA Approves Lutetium Lu 177 Dotatate for SSTR-Positive Gastroenteropancreatic Neuroendocrine Tumors

By: Dr. Anish Shah Bronx-Lebanon Hospital; Bronx, NY On April 23, 2024, the U.S. Food and Drug…

7 months ago

FDA Approves Alectinib for Adjuvant Treatment in Non-Small Cell Lung Cancer

By: Dr. Anish Shah Bronx-Lebanon Hospital; Bronx, NY On April 18, 2024, the U.S. Food and Drug…

7 months ago